H. Lundbeck A/S
Lundbeck is a pharmaceutical company engaged in the research, development, production, marketing and sale of CNS pharmaceuticals across the world. We target depression and anxiety, psychotic diseases, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.
Key staff involved in EBiSC
Jan Egebjerg (Vice President) – Dr. Jan Egebjerg is responsible for the Neurodegenerative discovery at Lundbeck. He has for over 20 years been involved in drug discovery from target identification and validation to translational medicine, within neurodegenerative and psychiatric diseases. Jan Egebjerg is vice chair for” Patient-Specific Stem Cell Derived Models for Alzheimer´s Disease” a Danish advanced technology funded project.
Karina Fog (Director) – Dr. Karina Fog heads the discovery department Neurodegeneration 1. She has 19 years’ experience in Drug Discovery on cell based disease models, target finding screens and target validation. Current focus in the department is late-stage neurodegenerative disease projects, biomarker initiatives, as well as identification and validation of novel drug targets addressing misfolded proteins in neurodegeneration.
Tina C. Stummann (Research Scientist) – Dr. Tina Stummann leads Lundbeck’s stem cell group. She has 7+ years of experience in electrophysiology, neuronal differentiation of pluripotent stem cells and establishment of stem cell based in vitro models. Her current primary work task is establishment of Alzheimer’s disease and Frontotemporal dementia based on iPSC from patients. Participation in international ESC EC framework projects.
More information: www.lundbeck.com »